Clinical Trials, Corporate Transparency
GlaxoSmithKline PLC settled a suit brought against it in June by New York State attorney general Eliot Spitzer, who had charged the company with hiding clinical trial data about its blockbuster antidepressant paroxetine (Paxil), but the pharmaceutical industry as a whole is experiencing repercussions. Now PhRMA advocates publishing all Phase III trials for approved drugs.
You may also be interested in...
Lilly sees its own credibility problem, and the industry's, as a major financial challenge--compromising approvals, marketing claims and pricing. It also contends its solution, providing far more information about its products through its marketing and R&D organizations, provides a solution for the industry as a whole. But as it's been rolled out so far, the strategy will disproportionately benefit Lilly.
In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.